Maternal and cord blood plasma samples from 22 mother-cord dyads who were previously infected with SARS-CoV-2 and 34 uninfected, contemporaneously-enrolled mother-neonate dyads were collected at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) at the time of delivery (Shook et al., 2020). Placental samples collected from a subset of enrolled participants were fixed at the time of delivery and utilized for immunohistochemical analyses. Maternal and cord blood plasma from an additional third trimester validation cohort comprised of 28 mother-neonate dyads and a second trimester cohort comprised of 29 mother-neonate dyads was collected from participants enrolled at the same institutions. Individuals were tested for SARS-CoV-2 by real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) of nasopharyngeal swab. Neonates born to COVID+ mothers were tested for SARS-CoV-2 via RT-PCR of nasopharyngeal swab, as per hospital policy. Maternal disease severity was determined based on published criteria from the Society for Maternal-Fetal Medicine and the National Institutes of Health. All enrolled participants provided informed consent. This study was approved by the MGH-BWH (Mass General Brigham) Institutional Review Board.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.